# γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant

> **NCT07123662** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Guangzhou Bio-gene Technology Co., Ltd** · enrollment: 8 (estimated)

## Conditions studied

- Leukemia
- Myeloid
- Acute

## Interventions

- **BIOLOGICAL:** Gamma-Delta T cell injection
- **OTHER:** Standard prophylactic treatment

## Key facts

- **NCT ID:** NCT07123662
- **Lead sponsor:** Guangzhou Bio-gene Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2028-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123662, "γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07123662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*